These effects likely underpin the substantial cardiovascular benefits associated with GLP-1 RA therapy, including reduced risk, severity, and complications of atherosclerosis [121], myocardial infarction, arrhythmias, heart failure, and MACE (Table 5). This evidence concerns the gene GLP1R and myocardial infarction.